Thermo Fishr Sci SEC Filings

Marc N. Casper, Chairman & CEO of Thermo Fisher Scientific (TMO), reported multiple transactions on Form 4. On 08/19/2025 and 08/20/2025 the filing shows purchases of common stock (totaling 496 shares) at $253.99 and contemporaneous sales of common stock (totaling 496 shares) at a weighted-average price near $500.17. Following the reported trades, the filing lists total beneficial ownership of common stock at approximately 115,173.623 shares (direct) plus several indirect holdings: 11,300, 14,608, and 5,000 shares via trusts or entities. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted April 28, 2025, and includes option-related entries showing acquisition of stock options with underlying shares of 201 and 295 that vest/exercisable per earlier vesting dates.

Form 144 notice for proposed sale of Thermo Fisher Scientific, Inc. (TMO) securities. The filer reports offering 295 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $147,512.35 and an approximate sale date of 08/20/2025. The filing lists 377,612,121 shares outstanding. The securities to be sold were acquired on 08/20/2025 by exercise of an option originally granted on 02/26/2019, and the payment method is indicated as cash. The filing also discloses securities sold during the past three months by Marc N. Casper totaling 18,201 shares for aggregate gross proceeds of $8,254,290.17. The notice includes the standard representation that the seller does not possess undisclosed material adverse information and contains the routine attestations required by Rule 144.

Thermo Fisher Scientific (TMO) Rule 144 notice shows an insider proposes to sell 201 shares of common stock through Fidelity Brokerage, with an aggregate market value of $100,533.57 based on the filing. The shares are reported as acquired via an option granted on 02/26/2019 and exercised/dated 08/19/2025 with cash payment. The filer has aggregated recent dispositions: Marc N. Casper sold 10,000 shares on 08/06/2025 for $4,518,207.00 and 8,000 shares on 08/07/2025 for $3,635,549.60. The notice includes the standard insider representation that no material nonpublic information is known.

Form 144 notice for Thermo Fisher Scientific, Inc. (TMO): An owner proposes to sell 11,440 common shares through Fidelity Brokerage Services on the NYSE with an approximate sale date of 08/19/2025. The filing reports an aggregate market value of $5,671,128.27 and a total of 377,612,121 shares outstanding, and indicates the shares were acquired under an option granted on 09/09/2020 with the acquisition dated 08/19/2025. Payment for the sale is listed as cash. The filer certifies they are not aware of any undisclosed material adverse information and notes there were no sales in the past three months by the same person.

Thermo Fisher Scientific (TMO) – Form 4 insider activity

Chairman & CEO Marc N. Casper exercised 18,000 previously vested employee stock options at a $253.99 strike price on 6–7 Aug 2025 and immediately sold the same number of shares under a pre-arranged Rule 10b5-1 plan. Weighted-average sale prices ranged from $446.92 to $456.41, implying gross proceeds of roughly $8.4 million and an intrinsic gain of about $3.6 million versus the $4.6 million exercise cost. These trades are coded “M/S,” indicating routine option exercise and sale.

After the transactions, Casper’s direct stake remains essentially unchanged at 115,173 common shares (≈$52 million at the sale prices). He also reports indirect ownership of 30,908 shares through family trusts and a private entity. Option holdings declined to 35,250 shares expiring 26 Feb 2026.

• No impact on Thermo Fisher’s cash; shares came from option conversion.
• Continued large equity position suggests ongoing alignment, although repeated same-day sales could be viewed as mild insider-selling pressure.

Thermo Fisher Scientific (TMO) – Form 144 filing. An insider, identified in the filing’s past-sales table as Marc N. Casper, has given notice of intent to sell up to 8,000 common shares through Fidelity Brokerage on the NYSE.

The shares have an aggregate market value of $3.64 million (≈$455 per share). With 377.6 million shares outstanding, the proposed sale equals roughly 0.002 % of the float, signalling an immaterial ownership impact and no dilution.

The insider also reported a recent sale of 10,000 shares on 08-06-2025 for $4.52 million. Form 144 is a pre-trade notice; execution is not guaranteed, and the filer attests to possessing no undisclosed adverse information. The document contains no operational, earnings or strategic updates.

Thermo Fisher Scientific’s Q2-25 results show modest growth, lower margins and weaker cash conversion.

Total revenue rose 3% YoY to $10.86 b; product sales +1%, services +5%. Operating income edged up 1% to $1.83 b but margin slipped 40 bp to 16.9% after $82 m of restructuring charges. Net income attributable to TMO increased 4.5% to $1.62 b; diluted EPS climbed 6% to $4.28.

For six months, revenue reached $21.22 b (+1.6%) and EPS $8.26 (+10%). Operating cash flow fell 34% to $2.12 b as inventories (+12%) and receivables (+5%) expanded. The company repurchased $2.0 b of shares, paid $311 m in dividends and issued $2.84 b of new debt, lifting total borrowings to $35.3 b (par) while cash rose to $4.58 b.

Segment revenue YoY: Life Sciences Solutions +6% ($2.50 b); Analytical Instruments −3% ($1.73 b); Specialty Diagnostics +1% ($1.13 b); Laboratory Products & Biopharma Services +4% ($6.00 b). Growth came from North America (+3%) and Europe (+6%); Asia-Pacific declined 3%.

The effective tax rate dropped to 5.6% YTD (vs 12.2%) thanks to a $153 m deferred-tax benefit on intra-entity transfers. Management expects another ~$140 m of restructuring, mainly in Laboratory Products.

Investor focus: steady EPS aided by tax gains, soft operating margin, cash-flow pressure, and higher leverage partially offset by strong liquidity.

Thermo Fisher Scientific (TMO) — Form 4 insider transaction

Executive Vice President Gianluca Pettiti reported the sale of 400 common shares on 07/25/2025 at $479.98 per share, generating roughly $0.19 million in proceeds. The trade was executed under a Rule 10b5-1 plan that Pettiti adopted on 02/10/2025, indicating it was pre-scheduled and not based on current market conditions.

Post-transaction, the executive directly owns 22,366.925 shares. No derivative securities were bought or sold and no indirect holdings were reported. The filing discloses no additional company fundamentals or other insider activity.

• Transaction size is modest relative to Pettiti’s remaining stake, suggesting continued alignment with shareholders.
• No impact on share count or control structure; purely a personal liquidity event.